Premium
HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women
Author(s) -
VOGELVANG T. E.,
LEURS J. R.,
MIJATOVIC V.,
WILLEMSE J.,
VAN DER MOOREN M. J.
Publication year - 2005
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2005.01306.x
Subject(s) - fibrinolysis , selective estrogen receptor modulator , estrogen , placebo , randomized controlled trial , medicine , pharmacology , estrogen receptor , postmenopausal women , menopause , endocrinology , pathology , cancer , alternative medicine , breast cancer